Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 15/20 | 0.57 |
| ▸ | KDR | P35968 | 9/20 | 0.55 |
| ▸ | EGFR | P00533 | 7/20 | 0.52 |
| ▸ | LCK | P06239 | 2/20 | 0.52 |
| ▸ | YES1 | P07947 | 2/20 | 0.52 |
| ▸ | CSK | P41240 | 2/20 | 0.52 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.52 |
| ▸ | GAK | O14976 | 1/20 | 0.52 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.52 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.52 |
| ▸ | STK10 | O94804 | 1/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | FYN | P06241 | 1/20 | 0.52 |
| ▸ | LYN | P07948 | 1/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | HCK | P08631 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | FGR | P09769 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22901501 | 1.00 | SRC (0.57) | SRCKDREGFRLCKYES1 | |
| SCHEMBL22901476 | 1.00 | SRC (0.57) | SRCKDREGFRLCKYES1 | |
| SCHEMBL21474550 | 0.93 | SRC (0.65) | SRCKDREGFRLCKYES1 | |
| SCHEMBL21473415 | 0.93 | SRC (0.65) | SRCKDREGFRLCKYES1 | |
| SCHEMBL21473403 | 0.93 | SRC (0.65) | SRCKDREGFRLCKYES1 | |
| SCHEMBL21462177 | 0.92 | SRC (0.68) | SRCKDREGFRLCKYES1 | |
| SCHEMBL21465858 | 0.92 | SRC (0.68) | SRCKDREGFRLCKYES1 | |
| SCHEMBL21462176 | 0.92 | SRC (0.68) | SRCKDREGFRLCKYES1 | |
| SCHEMBL21473414 | 0.86 | SRC (0.56) | SRCKDREGFRLCKYES1 | |
| SCHEMBL21473395 | 0.86 | SRC (0.56) | SRCKDREGFRLCKYES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713306-B2 | 5-substituted difluoropiperidine compounds with blood-brain barrier penetrable capability | WAYSHINE BIOPHARM HOLDING LIMITED (KY) | 2023-08-01 | — | — | US | disclosed |
| US-11713306-B2 | 5-substituted difluoropiperidine compounds with blood-brain barrier penetrable capability | WAYSHINE BIOPHARM HOLDING LIMITED (KY) | 2023-08-01 | — | — | US | disclosed |
| CN-110357858-B | 5-substituted difluoropiperidine compounds having blood-brain barrier crossing capability | 威尚（上海）生物医药有限公司 | 2022-02-18 | — | — | CN | disclosed |
| US-20210017159-A1 | 5-SUBSTITUTED DIFLUOROPIPERIDINE COMPOUNDS WITH BLOOD-BRAIN BARRIER PENETRABLE CAPABILITY | WEISHANG (SHANGHAI) BIO-PHARMACEUTICAL CO., LTD. (CN) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713306-B2 | 5-substituted difluoropiperidine compounds with blood-brain barrier penetrable capability | FYN, KDR, FLT1 | SRC 9/4885KDR 2/4885EGFR 11/4885 |
| US-20210017159-A1 | 5-SUBSTITUTED DIFLUOROPIPERIDINE COMPOUNDS WITH BLOOD-BRAIN BARRIER PENETRABLE CAPABILITY | FYN, KDR, FLT1 | SRC 9/4885KDR 2/4885EGFR 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.